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Background:  New  vaccines  containing  highly  conserved  Streptococcus  pneumoniae  proteins  such  as  pneu-
molysin  toxoid  (dPly)  and  histidine-triad  protein  D  (PhtD)  are  being  developed  to  provide  broader
protection  against  pneumococcal  disease.  This  study  evaluated  the  safety,  reactogenicity  and  immuno-
genicity  of  different  pneumococcal  protein-containing  formulations  in  adults.
Methods: In a phase  I double-blind  study  (www.clinicaltrials.gov: NCT00707798),  healthy  adults  (18–40
years)  were randomized  (1:2:2:2:2:2:2)  to receive  two doses  of one  of  six investigational  vaccine  formu-
lations 2 months  apart,  or  a single  dose  of  the control  23-valent  pneumococcal  polysaccharide  vaccine
(23PPV;  Pneumovax23TM, Sanoﬁ  Pasteur  MSD)  followed  by  placebo.  The  investigational  formulations
contained  dPly  alone  (10  or  30  g), or both  dPly  and  PhtD  (10 or 30 g  each)  alone  or combined  with
the polysaccharide  conjugates  of  the 10-valent  pneumococcal  non-typeable  Haemophilus  inﬂuenzae  pro-
tein D  conjugate  vaccine  (PHiD-CV;  SynﬂorixTM, GlaxoSmithKline  Vaccines).  Two  groups  primed  with
a  formulation  containing  dPly  and PhtD  (10  or  30  g each)  continued  to the  follow-up  phase  II  study
(NCT00896064),  in which  they  received  a booster  dose  at 5–9  months  after  primary  vaccination.
Results:  Of  156  enrolled  and vaccinated  adults,  146  completed  the  primary  immunization  and  43 adults
received  a booster  dose.  During  primary  and  booster  vaccination,  for any  formulation,  ≤8.9%  of  doses  were
followed  by grade  3 solicited  local or general  adverse  events.  No  fever  >39.5 ◦C (oral  temperature)  was
reported.  Unsolicited  adverse  events  considered  causally  related  to  vaccination  were  reported  following
≤33.3% of investigational  vaccine  doses.  No  serious  adverse  events  were  reported  for  adults  receiving
investigational  vaccine  formulations.  Formulations  containing  dPly  with  or without  PhtD were  immuno-
genic  for  these  antigens;  polysaccharide  conjugate-containing  formulations  were  also  immunogenic  for
those 10  polysaccharides.
Conclusion:  Investigational  vaccine  formulations  containing  dPly  and  PhtD  were  well tolerated  and
immunogenic  when  administered  to healthy  adults  as  standalone  protein  vaccine  or combined  with
PHiD-CV  conjugates.
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. Introduction
Streptococcus pneumoniae is frequently involved in common
ucosal bacterial infections such as pneumonia, and can lead
o invasive disease including sepsis, meningitis and invasive
neumonia [1,2]. Worldwide, this pathogen is responsible for
pproximately 11% of mortality in children under 5 years old [2].
Pneumococcal conjugate vaccines (PCVs) have decreased the
urden of pneumococcal disease in children in many countries
nd provided indirect effect in decreasing vaccine-type disease in
on-vaccinated populations [3–5]. However, shifts in serotype epi-
emiology have occurred and consequently considerable disease
urden remains, largely owing to serotypes not included in the
urrently used PCVs [4–6].
The use of highly conserved pneumococcal proteins as vaccine
ntigens has the potential to provide broader protection against
neumococcal disease than PCVs. Two candidate antigens for a
rotein-based pneumococcal vaccine are pneumolysin (Ply) and
istidine-triad protein (PhtD). Ply is a thiol-dependent toxin that
s present in nearly all pneumococcal serotypes [7]. Its toxoid
erivatives (dPly) induce protection against pneumococcal infec-
ion in animal models [8–11]. PhtD is exposed on the surface of
ntact bacteria [12] and may  be involved in lung-speciﬁc viru-
ence [13]. Immunization with PhtD elicits functional antibodies
14–16] and provides protection against pneumonia in animal
odels [11,15]. Antibodies against PhtD prevent pneumococcal
dherence to human airway epithelial cells [16]. An investiga-
ional vaccine containing 10 or 30 g PhtD was shown to have an
cceptable reactogenicity proﬁle in adults, with no safety concerns,
nd dose-dependent immunogenicity when comparing the 10 and
0 g formulations [17].
This phase I study provides a safety and reactogenicity
ssessment of investigational pneumococcal protein-containing
ormulations in healthy adults before progressing to the target
ediatric population. We  evaluated six different formulations con-
aining dPly alone or with PhtD, or a combination of dPly and PhtD
ith the conjugates of the 10-valent pneumococcal non-typeable
aemophilus inﬂuenzae protein D conjugate vaccine (PHiD-CV).
fter the two-dose primary series, two primed cohorts received a
ooster dose of a 10 or 30 g dPly/PhtD formulation in the follow-
p phase II study.
. Methodology
.1. Study design and objectives
A phase I, randomized, controlled study (primary vaccination
tudy; NCT00707798) was conducted between June 2008 and
anuary 2009. Two groups were further evaluated in a follow-up
hase II study (booster vaccination study; NCT00896064) between
ay  and August 2009. Both studies were conducted at a single cen-
er in Belgium. The primary vaccination study was open in step 1
for the group receiving 10 g dPly). For steps 2 and 3 (encompass-
ng all other groups), data were collected in an observer-blinded
anner (vaccine recipients and those responsible for evaluation
f any study endpoint were unaware which vaccine was adminis-
ered) (Fig. 1).
The primary objective of both studies was to assess the safety
nd reactogenicity of the different investigational pneumococcal
accine formulations. Secondary objectives included evaluation of
he dPly and PhtD protein antibody responses. We  also evaluated
he non-typeable Haemophilus inﬂuenzae (NTHi) protein D antibody
anti-PD) response and opsonophagocytic activity (OPA) of vaccine
erotypes for the formulations containing capsular polysaccharide
onjugates (PS-conjugates). 32 (2014) 6838–6846 6839
The study protocols were approved by the Ethics Committee
of the Ghent University Hospital. The studies were conducted in
line with the Declaration of Helsinki and Good Clinical Practice.
Informed consent was obtained from each study participant before
enrolment.
These studies have been registered at www.clinicaltrials.gov
(NCT00707798; NCT00896064). Protocol summaries are avail-
able at http://www.gsk-clinicalstudyregister.com (GSK study IDs:
111651; 112993).
2.2. Participants and vaccines
Eligible participants were healthy adults (18–40 years old),
without a history of bacterial pneumonia or invasive pneumococ-
cal disease within 3 years before vaccination. Exclusion criteria
included vaccination with diphtheria/tetanus toxoids within 1
month preceding the ﬁrst study vaccine dose, and chronic adminis-
tration (>14 days) of immunosuppressants or immune-modifying
drugs within 6 months before vaccination. Participants were
screened by clinical laboratory analysis (supplementary methods);
those with hematological or biochemical abnormalities were not
enrolled. Participants were not to use any investigational or non-
registered product other than the study vaccine from 30 days before
the ﬁrst vaccine dose until study end. Women  of childbearing
potential were asked to practice adequate contraception from 30
days pre-vaccination until 2 months after completing the vaccina-
tion series.
Participants were enrolled sequentially in three steps preceded
by a safety review (Fig. 1). They were randomized (1:2:2:2:2:2:2,
block size 4 [step 1], 7 [step 2] and 5 [step 3]) using a central internet
randomization system (SBIR) to receive a two-dose primary vacci-
nation series with one of six investigational vaccine formulations
(GlaxoSmithKline Vaccines) or a single dose of the 23-valent pneu-
mococcal polysaccharide vaccine (23PPV; Pneumovax23TM, Sanoﬁ
Pasteur MSD) followed by placebo (150 mM NaCl) (Fig. 1; supple-
mentary methods). All vaccines and the placebo were administered
intramuscularly into the deltoid region of the non-dominant arm.
Two  investigational vaccines contained 10 or 30 g of dPly alone
(dPly-10 and dPly-30, respectively). Two  other formulations con-
tained both dPly and PhtD, each at a dose of 10 g (dPly/PhtD-10) or
30 g (dPly/PhtD-30). The remaining two  formulations contained
the 10 PHiD-CV PS-conjugates (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C,
19F and 23F) [18], in combination with 10 or 30 g of both dPly and
PhtD (PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30). Produc-
tion of PhtD and dPly is described in supplementary methods.
The control group received one dose of 23PPV, containing 25 g
of each capsular polysaccharide for pneumococcal serotypes 1, 2,
3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F,
20, 22F, 23F and 33F, and placebo (150 mM NaCl) as a second dose.
Participants from the dPly/PhtD-10 and dPly/PhtD-30 groups
were invited to participate in the booster vaccination study, to
receive a booster dose 5–9 months after completion of the two-dose
primary series.
2.3. Safety and reactogenicity assessment
Solicited local and general symptoms were recorded during the
7-day post-vaccination period and unsolicited adverse events (AEs)
during the 31-day post-vaccination period. Symptom intensity was
graded on a scale of 1 (mild) to 3 (severe). Grade 3 symptoms were
deﬁned as follows: for redness or swelling, a diameter >50 mm; for
fever, oral temperature >39.5 ◦C; and for all other events, preven-
ting normal activity.
Serious adverse events (SAEs) were recorded throughout the
duration of each study, and were deﬁned as any medical occurrence
that resulted in death, disability or incapacity, was life-threatening,
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Fig. 1. Study design Participants were enrolled in a sequential manner comprising three steps. A safety evaluation was completed prior to proceeding with the dosing or
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.4. Immunogenicity assessment
Blood samples for immunogenicity assays were collected before
rimary and booster vaccination, and 1 month after each dose.
erum samples were stored at −20 ◦C until analysis at Glaxo-
mithKline’s laboratory, Rixensart, Belgium and SGS laboratory,
avre, Belgium.
Antibodies were quantiﬁed using an in-house multiplex assay
oated with protein D, Ply (non-detoxiﬁed) and PhtD (supple-
entary methods), with assay cut-offs of 112 LU/mL for anti-PD,
99 LU/mL for anti-Ply and 391 LU/mL for anti-PhtD. These cut-offs
ere based on the lower limit of quantiﬁcation [19], the global vari-
bility of the assay at the highest dilution and the lower limit of
inearity. Participants with antibody levels below these technical
ut-offs were considered as antibody negative; however, as this is
ot a clinical cut-off, they were not considered true negatives.
Functional antibodies against the 10 serotype-speciﬁc PS-
onjugates of PHiD-CV were measured by a pneumococcal killing
ssay (OPA) with an opsonic titer cut-off of 8, as described previ-
usly [20].
.5. Statistical analysis
Safety analyses were performed on primary and booster
otal vaccinated cohorts (TVC). Immunogenicity analyses were
erformed on primary and booster according-to-protocol (ATP)
ohorts for immunogenicity, comprising participants who met  all
ligibility criteria, complied with protocol-deﬁned procedures, and
ith pre- and post-vaccination results available for at least one
ssay. All objectives were descriptive. The target sample size of the
rimary vaccination study was 156 participants: 12 for dPly-10; 24
or the remaining groups. With this sample size, the percentage of
articipants with grade 3 and related symptoms that would lead to
 signiﬁcant difference between groups with 80% power is 4% in the
ontrol group and 39.7% in the investigational formulation groups. visits at days 0 (dose 1), 1, 7, 30 (1 month post-dose 1), 60 (dose 2), 61, 67 and 90
), 1, 6 and 30 (1 month post-booster). aThe second dose in the control group was  a
Incidences of solicited and unsolicited AEs were calculated with
exact 95% conﬁdence intervals (CIs). Antibody geometric mean
concentrations (GMCs), OPA geometric mean titers (GMTs) and
seropositivity rates were calculated with their 95% CIs. GMCs and
GMTs were calculated by taking the anti-log10 of the mean of the
log10 antibody concentration or titer transformations. Antibody
concentrations/titers below assay cut-offs were given an arbitrary
value of half the cut-off for the purpose of GMC/GMT calculation.
Analyses were performed with Statistical Analysis System (SAS®
Institute Inc., Cary, NC).
3. Results
3.1. Study participants and demographics
Of 156 vaccinated adults, 146 completed the primary vacci-
nation study. 43 adults who  had received two  primary doses of
dPly/PhtD-10 or dPly/PhtD-30 completed the booster vaccination
study (Fig. 2). Demographic characteristics of the groups are shown
in Table 1.
3.2. Safety and reactogenicity of two-dose primary vaccination
3.2.1. Solicited local and general symptoms
Pain was the most commonly reported solicited local symptom
in all groups, reported by 41.7%–100% of participants post-dose
1 and 71.4%–95.2% post-dose 2 for investigational formulation
groups, and 91.7% post-dose 1 and 4.3% (one participant) post-dose
2 for the control group (Fig. 3A–C). Grade 3 local symptoms were
reported by up to three participants (0.0%–12.5%) post-dose 1 and
up to one participant (0.0%–4.8%) post-dose 2 in groups receiving
an investigational formulation, and by one participant (4.2%) post-
dose 1 and none of the participants post-dose 2 (placebo) in the
control group (Fig. 3A–C).
The most frequently reported solicited general symptoms were
fatigue and headache in the investigational groups and fatigue in
the control group. Fever was  reported by 0.0%–8.3% of participants
post-dose 1 and 0.0%–10.0% of participants post-dose 2 in the inves-
tigational groups, and by 4.2% post-dose 1 and 0.0% post-dose 2 in
G. Leroux-Roels et al. / Vaccine 32 (2014) 6838–6846 6841
Fig. 2. Participant ﬂow diagram. TVC, total vaccinated cohort; ATP, according to protocol; n, number of participants.
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ithdrawn from the study due to a SAE.
he control group. No grade 3 fever was reported in any group. No
rend for higher incidence rates of solicited general symptoms after
ose 2 compared to dose 1 was observed (Fig. 3D–I).
The combination of pneumococcal proteins with PS-conjugates
eemed to be associated with higher incidences of solicited local
nd general symptoms than the control vaccine (23PPV at dose 1,
lacebo at dose 2) (Fig. 3). The formulations containing the pneu-
ococcal proteins alone tended to be the least reactogenic.
.2.2. Unsolicited symptoms and serious adverse events
At least one unsolicited AE was reported after 44.7%–66.7% of
rimary investigational doses, and 46.8% of control doses. At least
ne grade 3 unsolicited AE was reported following 4.5%–13.3% of
rimary investigational doses, and 8.5% of control doses (Table S1).
t least one unsolicited AE considered causally related to vaccina-
ion was reported following 10.4%–33.3% of investigational vaccine
oses and 12.8% of control doses (Table S2).
No SAEs were reported in the investigational groups. One partic-
pant in the control group reported two SAEs (myalgia and skeletal
njury), which were considered not to be causally related to vacci-
ation.
.3. Safety and reactogenicity of the booster vaccination
.3.1. Solicited local and general symptoms
Pain was the most commonly reported solicited local symptom
n both groups post-booster (Fig. 3). Redness and swelling tended to
e reported more frequently following vaccination with the higher
rotein-content formulation than the lower protein-content for-
ulation. Grade 3 solicited local symptoms were reported by one
articipant in each group (Fig. 3).
Headache and fatigue tended to be reported more frequently in
he dPly/PhtD-30 group than in the dPly/PhtD-10 group, although
ne participant in the dPly/PhtD-10 group reported grade 3 fatiguesons for exclusion: study vaccine not administered according to protocol (n = 1),
hdrawn due to a non-serious AE, considered vaccine-related. No participants were
that was  considered to be vaccine-related. No other grade 3
solicited general symptoms were reported. Fever was  reported by
one participant (in the dPly/PhtD-10 group) (Fig. 3).
3.3.2. Unsolicited symptoms and serious adverse events
Unsolicited symptoms post-booster were reported by six par-
ticipants (27.3%) in the dPly/PhtD-10 group and ﬁve participants
(23.8%) in the dPly/PhtD-30 group. One participant in each group
reported a grade 3 unsolicited AE (pharyngitis [dPly/PhtD-10] and
upper respiratory tract infection [dPly/PhtD-30]). One participant
in each group reported an unsolicited AE that was considered
vaccine-related (aphthous stomatitis [dPly/PhtD-10] and periph-
eral edema in the right hand of a participant vaccinated in the left
arm [dPly/PhtD-30]). No SAEs were reported during the booster
study.
No clinically signiﬁcant changes in the hematology, biochem-
istry or urinary parameters were observed during the primary and
booster study (data not shown).
3.4. Immunogenicity
3.4.1. Immune response after two-dose primary vaccination
Before vaccination, all participants had anti-Ply and anti-PhtD
concentrations above the assays cut-offs. All remained seroposi-
tive post-dose 1 and post-dose 2. Anti-Ply antibody GMCs increased
after each vaccination in all groups except control. For PhtD, anti-
body GMCs increased following each vaccination in the groups that
received a PhtD-containing formulation. A trend toward higher
anti-Ply antibody GMCs was observed for dPly/PhtD compared to
dPly alone. Antibody GMCs tended to be higher for the 30 g for-
mulations when compared to the respective 10 g formulation,
although this trend was more pronounced for dPly (1.9- to 2.6-fold
higher) than PhtD (1.3- to 1.6-fold higher) (Table 2A and B).
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Table 1
Demographic characteristics of participants (total vaccinated cohort).
dPly-10 (n = 12) dPly-30 (n = 24) dPly/PhtD-10
(n = 24)
dPly/PhtD-30
(n = 24)
PHiD-
CV/dPly/PhtD-
10
(n = 24)
PHiD-
CV/dPly/PhtD-
30
(n = 24)
Control
(23PPV/placebo)
(n = 24)
Total (n = 156)
A. Primary vaccination study
Mean age at ﬁrst dose (years ± SD) 26.3 ± 5.74 25.8 ± 5.39 26.3 ± 5.17 23.3 ± 3.87 25.0 ± 6.53 23.0 ± 5.09 26.3 ± 6.90 25.0 ± 5.65
Female,  n (%) 4 (33.3) 14 (58.3) 16 (66.7) 14 (58.3) 14 (58.3) 15 (62.5) 15 (62.5) 92 (59.0)
Race,  n (%)
White–Caucasian/European heritage 11 (91.7) 24 (100) 24 (100) 24 (100) 24 (100) 24 (100) 24 (100) 155 (99.4)
Other  1 (8.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0.6)
dPly/PhtD-10 (n = 22) dPly/PhtD-30 (n = 21) Total (N = 43)
B. Booster vaccination study
Mean age at ﬁrst dose (years ± SD) 26.7 ± 4.80 23.9 ± 4.11 25.3 ± 4.64
Female,  n (%) 15 (68.2) 12 (57.1) 27 (62.8)
Race,  n (%)
White–Caucasian/European heritage 22 (100) 21 (100) 43 (100)
n, number of participants; SD, standard deviation
Table 2
Anti-Ply and anti-PhtD antibody geometric mean concentrations (according-to-protocol cohort for immunogenicity).
dPly-10  dPly-30  dPly/PhtD-10  Ply/PhtD-30  PHiD-CV/dPly/PhtD-10  PHiD-CV/dPly/PhtD-30  Control
N  GMC  (95%  CI)  N  GMC  (95%  CI)  N GMC  (95%  CI)  N  GMC  (95%  CI)  N  GMC  (95%  CI)  N  GMC  (95%  CI)  N GMC  (95%  CI)
A.  Anti-Ply  antibody  GMC  (LU/mL)
Pre-vac.  10  9198  (5993–14,115)  24  15,333  (10,751–21,867)  24  13,060  (9621–17,729)  23  14,905  (11,128–19,963)  24  12,239  (8648–17,320)  24  19,988  (15,149–26,371)  24  18,661  (12,727–27,363)
Post-dose 1 10  22,982  (15,631–33,790) 24  55,848  (37,181–83,887) 24  43,981  (31,936–60,568) 24  90,445  (62,894–130,065) 24  23,276  (16,926–32,009) 24  61,346  (46,049–81,725)  24  18,685  (12,612–27,683)
Post-dose 2 10  47,010  (30,960–71,379)  21  87,300  (58,202–130,947)  23  63,999  (48,406–84,614)  24  143,923  (106,150–195,138)  24  28,560  (21,331–38,239)  21  73,597  (52,250–103,665)  23  16,573  (11,007–24,954)
Pre-booster –  –  22  41,823  (30,264–57,797)  20  89,612  (65,851–121,947)  –  –  –
Post-booster –  –  22  92,943  (65,791–131303) 20  144767  (106912–196026) –  –  –
dPly-10 dPly-30  dPly/PhtD-10  dPly/PhtD-30  PHiD-CV/dPly/PhtD-10  PHiD-CV/dPly/PhtD-30  Control
N  GMC  (95%  CI) N  GMC  (95%  CI) N  GMC  (95%  CI) N  GMC  (95%  CI) N  GMC  (95%  CI) N  GMC  (95%  CI) N GMC  (95%  CI)
B.  Anti-PhtD  antibody  GMC  (LU/mL)
Pre-vac.  10  9997  (6609–15,121) 24  17,716  (13,161–23,849) 24  16,454  (11,491–23,561) 23  16,801  (13,271–21,271)  24  13,959  (10,650–18,297)  24  16,771  (11,893–23,650)  24  13,120  (10,035–17,153)
Post-dose 1 10  11,351  (6929–18,596)  24  18,095  (13,270–24,673)  24  28,637  (20,778–39,468)  24  37,186  (28,847–47,934)  24  22,446  (17,794–28,314)  24  29,021  (20,873–40,349)  24  12,904  (9568–17,402)
Post-dose 2  10  8054  (5005–12961)  21  14378  (10120–20429)  23  37,671  (29,311–48,414)  24  58,531  (49,364–69,401)  24  24,312  (18,801–31,439)  21  40,142  (29,095–55,382)  23  11,544  (8458–15,756)
Pre-booster –  –  22  26,672  (19,424–36,625)  20  42,111  (33,408–53,081)  –  –  –
Post-booster –  –  22  37,851  (29,018–49,371)  20  62,795  (51,696–76,278)  –  –  –
N, number of participants with available results; GMC, geometric mean concentration, 95% CI, 95% conﬁdence interval.
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Table 3
Percentage of participants with OPA titers ≥ 8, and OPA geometric mean titers of vaccine pneumococcal serotypes (according-to-protocol cohort for immunogenicity).
Sero-type PHiD-CV/dPly/PhtD-10 PHiD-CV/dPly/PhtD-30 Control (23PPV)
N % ≥ 8 (95% CI) GMT  (95% CI) N % ≥ 8 (95% CI) GMT  (95% CI) N % ≥ 8 (95% CI) GMT  (95% CI)
1 Pre-vac. 21 23.8 (8.2–47.2) 7.4 (4.2–13.0) 22 18.2 (5.2–40.3) 5.7 (4.0–8.0) 21 9.5 (1.2–30.4) 4.6 (3.8–5.7)
Post-dose  1 24 95.8 (78.9–99.9) 117.1 (67.7–202.5) 23 95.7 (78.1–99.9) 91.9 (56.0–150.9) 24 100 (85.8–100) 391.5 (193.7–791.4)
Post-dose 2 24 95.8 (78.9–99.9) 139.4 (83.8–231.9) 21 100 (83.9–100) 147.3 (98.7–219.8) 23 95.7 (78.1–99.9) 268.6 (129.0–559.2)
4 Pre-vac.  15 40.0 (16.3–67.7) 21.6 (6.2–75.5) 17 17.6 (3.8–43.4) 9.3 (3.5–24.8) 16 6.3 (0.2–30.2) 5.8 (2.6–12.7)
Post-dose  1 24 100 (85.8–100) 3468.8 (2091.4–5753.3) 24 100 (85.8–100) 5327.9 (3480.7–8155.3) 24 100 (85.8–100) 3335.4 (1902.8–5846.6)
Post-dose 2 23 100 (85.2–100) 2548.9 (1735.9–3742.7) 21 100 (83.9–100) 3845.0 (2573.6–5744.6) 23 95.7 (78.1–99.9) 1838.2 (855.4–3950.4)
5 Pre-vac.  24 16.7 (4.7–37.4) 5.7 (4.0–8.1) 23 0.0 (0.0–14.8) 4.0 (4.0–4.0) 23 8.7 (1.1–28.0) 5.5 (3.5–8.7)
Post-dose  1 23 95.7 (78.1–99.9) 266.9 (125.0–569.8) 24 95.8 (78.9–99.9) 202.5 (116.2–352.8) 24 100 (85.8–100) 416.9 (185.6–936.8)
Post-dose 2 24 95.8 (78.9–99.9) 212.9 (111.2–407.6) 21 100 (83.9–100) 225.7 (139.7–364.8) 23 91.3 (72.0–98.9) 180.9 (70.3–465.7)
6B Pre-vac.  13 76.9 (46.2–95.0) 144.9 (37.6–558.8) 12 66.7 (34.9–90.1) 122.9 (23.3–648.5) 10 70.0 (34.8–93.3) 141.7 (22.4–897.5)
Post-dose 1 24 100 (85.8–100) 991.5 (583.3–1685.2) 24 100 (85.8–100) 1775.1 (961.8–3276.3) 23 95.7 (78.1–99.9) 1724.5 (837.6–3550.7)
Post-dose 2 24 100 (85.8–100) 1202.7 (792.4–1825.3) 21 100 (83.9–100) 1935.8 (1193.7–3139.2) 23 91.3 (72.0–98.9) 940.3 (399.2–2214.7)
7F Pre-vac.  11 100 (71.5–100) 2107.1 (964.6–4602.7) 12 91.7 (61.5–99.8) 764.2 (193.3–3022.0) 14 85.7 (57.2–98.2) 586.5 (156.8–2194.4)
Post-dose 1 24 100 (85.8–100) 3239.0 (2209.1–4749.1) 24 100 (85.8–100) 4668.3 (2811.9–7750.4) 22 100 (84.6–100) 6960.6 (4531.6–10,691.5)
post-dose 2 24 100 (85.8–100) 4547.2 (3105.4–6658.4) 21 100 (83.9–100) 6056.7 (4211.8–8709.6) 23 100 (85.2–100) 4886.4 (2956.8–8075.1)
9V Pre-vac.  24 91.7 (73.0–99.0) 216.7 (103.5–453.8) 22 100 (84.6–100) 271.2 (177.8–413.6) 20 95.0 (75.1–99.9) 304.4 (148.5–624.0)
Post-dose 1 24 100 (85.8–100) 2037.4 (1208.5–3434.7) 24 100 (85.8–100) 2666.3 (1586.8–4480.2) 24 100 (85.8–100) 3945.9 (2390.3–6514.1)
Post-dose 2 24 100 (85.8–100) 3915.8 (2467.4–6214.3) 21 100 (83.9–100) 5498.0 (3334.3–9065.8) 23 100 (85.2–100) 2659.0 (1463.6–4830.9)
14 Pre-vac.  17 100 (80.5–100) 618.2 (364.9–1047.4) 16 93.8 (69.8–99.8) 245.2 (116.4–516.5) 20 95.0 (75.1–99.9) 308.4 (164.8–576.8)
Post-dose 1 24 100 (85.8–100) 2968.1 (1713.8–5140.3) 24 100 (85.8–100) 2559.1 (1651.0–3966.7) 24 100 (85.8–100) 3058.8 (1829.4–5114.2)
Post-dose 2 24 100 (85.8–100) 3045.5 (2007.2–4620.9) 21 100 (83.9–100) 2944.8 (1854.0–4677.5) 22 100 (84.6–100) 2551.9 (1518.7–4287.9)
18C Pre-vac.  18 33.3 (13.3–59.0) 11.0 (5.2–23.3) 20 20.0 (5.7–43.7) 9.0 (4.1–19.6) 18 22.2 (6.4–47.6) 9.3 (4.1–20.8)
Post-dose  1 24 95.8 (78.9–99.9) 562.2 (286.0–1105.0) 24 100 (85.8–100) 1132.3 (750.8–1707.6) 24 95.8 (78.9–99.9) 454.3 (217.1–950.7)
Post-dose 2 24 100 (85.8–100) 928.5 (613.2–1405.8) 21 100 (83.9–100) 1830.0 (1220.6–2743.7) 22 90.9 (70.8–98.9) 311.6 (134.9–719.5)
19F Pre-vac.  21 47.6 (25.7–70.2) 19.7 (7.8–49.8) 20 55.0 (31.5–76.9) 15.2 (7.7–30.1) 20 35.0 (15.4–59.2) 7.6 (4.9–11.7)
Post-dose  1 21 100 (83.9–100) 690.6 (374.4–1273.7) 23 100.0 (85.2–100) 2218.9 (1351.2–3643.6) 20 100 (83.2–100) 412.5 (189.4–898.4)
Post-dose 2 24 100 (85.8–100) 992.1 (532.9–1847.2) 21 100 (83.9–100) 2179.0 (1404.4–3380.9) 23 95.7 (78.1–99.9) 311.7 (141.7–685.6)
23F Pre-vac.  19 68.4 (43.4–87.4) 240.5 (58.6–987.6) 17 70.6 (44.0–89.7) 235.4 (55.6–996.7) 15 73.3 (44.9–92.2) 236.9 (56.8–988.4)
Post-dose 1 24 100 (85.8–100) 1968.9 (1256.5–3085.1) 24 100 (85.8–100) 3306.3 (2280.7–4793.1) 24 100 (85.8–100) 2024.2 (1237.8–3310.1)
Post-dose 2 24 100 (85.8–100) 1882.9 (1176.2–3014.3) 21 100 (83.9–100) 2987.4 (1977.1–4513.9) 23 95.7 (78.1–99.9) 1559.7 (778.7–3123.8)
N, number of participants for which the results were available; pre-vac., pre-vaccination; GMT, geometric mean titers; CI, conﬁdence interval.
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emained within the same ranges as post-dose 1 (data not
hown).
At both 1 month post-dose 1 and 1 month post-dose 2, for each
accine pneumococcal serotype, at least 95.7% of participants in the
HiD-CV/dPly/PhtD groups had OPA titers ≥8. In the control group,
hese percentages were at least 95.7% 1 month post-dose 1 (23PPV)
nd at least 90.9% 1 month after dose 2 (placebo), compared to at
east 6.3% before vaccination (Table 3).
After each primary dose, for 7 of 10 pneumococcal serotypes,
bserved OPA GMTs seemed to be higher in the PHiD-
V/dPly/PhtD-30 group than in the PHiD-CV/dPly/PhtD-10 group.
or several pneumococcal serotypes, increases in OPA GMTs from
ost-dose 1 to post-dose 2 were observed (Table 3).
.4.2. Persistence and post-booster immune response to dPly and
htD
Before and 1 month post-booster, all participants in the
Ply/PhtD-10 and dPly-PhtD-30 groups had antibody concen-
rations ≥599 LU/mL for anti-Ply and ≥391 LU/mL for anti-PhtD
ntibodies.
Anti-Ply and anti-PhtD antibody GMCs decreased between the
ost-dose 2 and pre-booster timepoint. For both the 10 and 30 g
ormulations, a trend for increased anti-Ply and anti-PhtD anti-
ody GMCs was observed post-booster compared to pre-booster.
ost-booster antibody GMCs were in a similar range as those post-
ose 2, except for dPly in the dPly/PhtD-10 group (63,999 LU/mL
ost-dose 2, 92,943 LU/mL post-booster). A trend toward higher
nti-Ply and anti-PhtD antibody GMCs was observed pre- and post-
ooster with the PHiD-CV/dPly/PhtD-30 formulation compared to
he PHiD-CV/dPly/PhtD-10 formulation (Table 2A and B).
. Discussion
We  assessed the safety and immunogenicity of six investi-
ational pneumococcal protein-containing vaccine formulations.
ll had an acceptable safety proﬁle and were well tolerated. No
accine-related SAEs were reported. Vaccination with subsequent
oses did not lead to increased incidence of solicited symptoms or
nsolicited AEs.
There was a trend toward higher incidences of solicited
ymptoms for the combination of pneumococcal proteins with PS-
onjugates than for the control vaccine (particularly redness and
welling). This higher reactogenicity in adults could be related to
he carrier proteins of the polysaccharides [21,22]; reactogenicity
roﬁles may  differ in young children, the main target group.
Reactogenicity of the formulations containing pneumococcal
roteins alone (dPly and dPly/PhtD) was low, and generally in a
imilar range as previously reported for other investigational pneu-
ococcal protein vaccines containing dPly [23], PhtD [24] or a
ombination of PhtD and pneumococcal choline-binding protein
 (PcpA) [25].
Initial immunogenicity assessments in this small group of
dults showed an increase in anti-PhtD and/or anti-Ply antibody
MCs following each investigational vaccine dose. Coadministra-
ion of dPly with PhtD did not negatively affect anti-Ply antibody
esponses. There was a trend toward higher anti-Ply antibody
MCs for dPly/PhtD than for dPly alone. Our results thus conﬁrm
he immunogenicity of both antigens, in-line with previous stud-
es [26,27], and suggest that PhtD enhances the anti-Ply immune
esponse. One prospective study reported an increase over time in
he levels of natural antibodies against ﬁve pneumococcal proteins
including PhtD and Ply) in young children with nasopharyngeal
olonization and acute otitis media [26]. Adults have been shown
o have circulating memory CD4+ T cells that can be stimulated by
htD, Ply and other protein vaccine candidate antigens [27]. Young 32 (2014) 6838–6846 6845
children have a more limited response, indicating that their vac-
cination would likely require several priming doses to stimulate
CD4+ T-cell responses [27].
Before vaccination, all participants already had anti-Ply and
anti-PhtD antibody concentrations above the assay cut-off. This
high pre-vaccination seropositivity rate most likely reﬂects pre-
vious pneumococcal exposure. In infants and toddlers, increases
in naturally-acquired antibody levels against several pneumococ-
cal protein surface antigens (including PhtD) and Ply have been
reported with increasing age (from 6 months to 2 years) and
exposure (nasopharyngeal carriage, acute otitis media) [26,28–30].
Otitis-prone children and children with treatment failure of acute
otitis media also mount a lower IgG serum antibody response
to pneumococcal proteins [31]. Several studies have indicated a
protective role of naturally acquired anti-Ply antibodies [32,7,33],
while antibodies against PhtD prevent pneumococcal adherence to
human airway epithelial cells [16]. The presence of these antibod-
ies, as seen in our participants, could thus be contributing to the
protection of healthy young adults against pneumococcal disease.
Our immunogenicity results must be interpreted with caution
due to the small number of participants and the fact that protective
levels of antibodies to pneumococcal proteins have not yet been
determined. Additionally, our study was performed in adults aged
18–40 years; these results serve as a safety assessment before pro-
gressing to a pediatric population but may  not reﬂect the safety,
reactogenicity and immunogenicity data from other age groups.
Because PHiD-CV is not licensed for use in adults, no PHiD-CV con-
trol group was included and we  could thus not assess whether
addition of the proteins affects PS-conjugate responses.
Our results support continued development of the investi-
gational pneumococcal protein-containing vaccine and further
assessment in younger age groups, who  carry the main burden
of pneumococcal disease. New pneumococcal protein-containing
vaccines are promising and have the potential to also target the
serotypes that are currently not covered by PCVs.
Synﬂorix is a trademark of the GlaxoSmithKline group of com-
panies; Pneumovax23 is a trademark of Sanoﬁ Pasteur.
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